Bradley W Blaser, MD, PhD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, where I seek to identify factors in the hematopoietic niche that promote the development of myeloid neoplasia. My current research involves using samples from the OSUCCC Leukemia Tissue Bank to find candidate genes that will be screened for effects on blood stem cells in the zebrafish system using genetic gain- and loss-of-function approaches. Cell biological and molecular mechanisms are then studied down to the single cell level using time-lapse video microscopy, flow cytometry and next-generation sequencing techniques to identify factors that may be useful in improving hematopoietic reconstitution in patients undergoing hematopoietic stem cell transplantation. I have co-authored many articles in scientific journals such as Blood, Leukemia Research and Journal of Immunology, and have presented my findings to the American Society of Hematology and the International Congress of Immunology.
Clinical Expertise
More info for- Hematology
Education & Training
More info forFellowship - Hematology & Oncology
- Boston Children's Hospital
300 Longwood Ave, Boston, MA
Internship - Internal Medicine
- Brigham & Women's Abdominal Imaging Fellowship
75 Francis St, Boston, MA
Residency - Internal Medicine
- Brigham & Women's Abdominal Imaging Fellowship
75 Francis St, Boston, MA
Fellowship - Hematology & Oncology
- Dana-Farber Cancer Institute
44 Binney St, Boston, MA
Medical School
- Ohio State University College of Medicine
370 W 9Th Ave, Columbus, OH
- Boston Children's Hospital
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0424
410 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-2341Email:
blaser.4@osu.eduVideos
More info forPublications
More info forApril 15, 2024CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival.
Wedig J, Jasani S, Mukherjee D, Lathrop H, Matreja P, Pfau T, D'Alesio L, Guenther A, Fenn L, Kaiser M, Torok MA, McGue J, Sizemore GM, Noonan AM, Dillhoff ME, Blaser BW, Frankel TL, Culp S, Hart PA, Cruz-Monserrate Z, Mace TA
Cancer Immunol Immunother
January 9, 2024Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason C, Alinari L, Blaser BW, Baiocchi R
Blood Adv
January 1, 2024In vivo monitoring of leukemia-niche interactions in a zebrafish xenograft model.
Arner A, Ettinger A, Blaser BW, Schmid B, Jeremias I, Rostam N, Binder-Blaser V
PLoS One
November 28, 2023Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE
Mol Cancer Res
October 2, 2023Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma.
Long ME, Koirala S, Sloan SL, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason CE, Alinari L, Blaser BW, Baiocchi RA
Blood Adv
May 18, 2023Microenvironmental control of hematopoietic stem cell fate via CXCL8 and protein kinase C.
Binder V, Li W, Faisal M, Oyman K, Calkins DL, Shaffer J, Teets EM, Sher S, Magnotte A, Belardo A, Deruelle W, Gregory TC, Orwick S, Hagedorn EJ, Perlin JR, Avagyan S, Lichtig A, Barrett F, Ammerman M, Yang S, Zhou Y, Carson WE, Shive HR, Blachly JS, Lapalombella R, Zon LI, Blaser BW
Cell Rep
January 6, 2023Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R
Nat Commun
July 13, 2022A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells.
Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, Blaser BW, Huszar D, Helmig-Mason J, Zhang L, Schrock MS, Summers MK, Chan WK, Prouty A, Mundy-Bosse BL, Chen-Kiang S, Danilov AV, Maddocks K, Baiocchi RA, Alinari L
Exp Hematol Oncol
July 7, 2022BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.
Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD, Blaser BW
Blood Adv
September 1, 2021Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C
Blood Cancer Discov
September 4, 2020Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B
Int J Hematol Oncol
June 1, 2020CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson Iii WE, Mace TA
J Immunother Cancer
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Blaser has reported no relationships with companies or entities.